Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Loss of TIPE3 reduced the proliferation, survival and migration of lung cancer cells through inactivation of Akt/mTOR, NF-κB, and STAT-3 signaling cascades.

Authors:
Devivasha Bordoloi Choudhary Harsha Ganesan Padmavathi Kishore Banik Bethsebie Lalduhsaki Sailo Nand Kishor Roy Sosmitha Girisa Krishan Kumar Thakur Amrita Devi Khwairakpam Arunachalam Chinnathambi Tahani Awad Alahmadi Sulaiman Ali Alharbi Mehdi Shakibaei Ajaikumar B Kunnumakkara

Life Sci 2022 Mar 15;293:120332. Epub 2022 Jan 15.

Cancer Biology Laboratory and DBT-AIST International Center for Translational and Environmental Research (DAICENTER), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India. Electronic address:

Lung cancer is the foremost cause of cancer related mortality among men and one of the most fatal cancers among women. Notably, the 5-year survival rate of lung cancer is very low; 5% in developing countries. This low survival rate can be attributed to factors like late stage diagnosis, rapid postoperative recurrences in the patients undergoing treatment and development of chemoresistance against different agents used for treating lung cancer. Therefore, in this study we evaluated the potential of a recently identified protein namely TIPE3 which is known as a transfer protein of lipid second messengers as a lung cancer biomarker. TIPE3 was found to be significantly upregulated in lung cancer tissues indicating its role in the positive regulation of lung cancer. Supporting this finding, knockout of TIPE3 was also found to reduce the proliferation, survival and migration of lung cancer cells and arrested the G2 phase of cell cycle through inactivation of Akt/mTOR, NF-κB, STAT-3 signaling. It is well evinced that tobacco is the major risk factor of lung cancer which affects both males and females. Therefore, this study also evaluated the involvement of TIPE3 in tobacco mediated lung carcinogenesis. Notably, this study shows for the first time that TIPE3 positively regulates tobacco induced proliferation, survival and migration of lung cancer through modulation of Akt/mTOR signaling. Thus, TIPE3 plays critical role in the pathogenesis of lung cancer and hence it can be specifically targeted to develop novel therapeutic strategies.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lfs.2022.120332DOI Listing
March 2022

Publication Analysis

Top Keywords

lung cancer
44
migration lung
12
proliferation survival
12
cancer
12
survival migration
12
lung
12
survival rate
8
stat-3 signaling
8
nf-κb stat-3
8
akt/mtor nf-κb
8
inactivation akt/mtor
8
cancer cells
8
study evaluated
8
tipe3
6
survival
5
positive regulation
4
regulation lung
4
cancer supporting
4
supporting finding
4
finding knockout
4

Keyword Occurance

Similar Publications

Concurrent Ocular Myopathy and Myasthenia Gravis After Zimberelimab Therapy in a Patient With Non-Small-Cell Lung Cancer.

Authors:
Haelim Kim Jong-Seok Lee Jun-Soon Kim Kyung Seok Park

J Clin Neurol 2022 May;18(3):364-366

Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

View Article and Full-Text PDF
May 2022
Similar Publications

Integrating Heart Failure Palliative Care Delivery in an Uncertain Disease Trajectory.

Authors:
Gursharan K Singh Caleb Ferguson Louise D Hickman

Heart Lung Circ 2022 Jun;31(6):755-756

University of Wollongong, Wollongong, NSW, Australia.

View Article and Full-Text PDF
June 2022
Similar Publications

Association of volumetric-modulated arc therapy with radiation pneumonitis in thoracic esophageal cancer.

Authors:
Hiroyuki Inoo Katsuyuki Sakanaka Kota Fujii Yuichi Ishida Takashi Mizowaki

J Radiat Res 2022 May 20. Epub 2022 May 20.

Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.

The lung volume receiving low-dose irradiation has been reported to increase in volumetric-modulated arc radiotherapy (VMAT) compared with three-dimensional conformal radiotherapy (3DCRT) for thoracic esophageal cancer, which raises concerns regarding radiation pneumonitis (RP) risk. This single institutional retrospective cohort study aimed to explore whether VMAT for thoracic esophageal cancer was associated with RP. Our study included 161 patients with thoracic esophageal cancer, of whom 142 were definitively treated with 3DCRT and 39 were treated with VMAT between 2008 and 2018. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Phenotypic and functional characterizations of CD8 T cell populations in malignant pleural effusion.

Authors:
Yaoxin Zhang Wenhui Li Jiawei Zhai Yujia Jin Lianjun Zhang Cheng Chen

Exp Cell Res 2022 May 16:113212. Epub 2022 May 16.

Department of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China. Electronic address:

Malignant pleural effusions (MPE) are a common terminal pathway for many types of cancer, especially non-small cell lung cancer (NSCLC). However, the phenotype and differentiation status of MPE-infiltrating CD8 T cells have not yet been systematically addressed. In this study, the surface molecules and cytokine secretion of T cells in MPE and peripheral blood (PB) were analyzed using flow cytometry. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.

Authors:
Marjorie G Zauderer Peter W Szlosarek Sylvestre Le Moulec Sanjay Popat Paul Taylor David Planchard Arnaud Scherpereel Marianna Koczywas Martin Forster Robert B Cameron Tobias Peikert Evren Kocabaş Argon Neil R Michaud Attila Szanto Jay Yang Yingxue Chen Vikram Kansra Shefali Agarwal Dean A Fennell

Lancet Oncol 2022 May 16. Epub 2022 May 16.

Leicester Cancer Research Centre, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK. Electronic address:

Background: Treatment options for malignant pleural mesothelioma are scarce. Tazemetostat, a selective oral enhancer of zeste homolog 2 (EZH2) inhibitor, has shown antitumour activity in several haematological cancers and solid tumours. We aimed to evaluate the anti-tumour activity and safety of tazemetostat in patients with measurable relapsed or refractory malignant pleural mesothelioma. Read More

View Article and Full-Text PDF
May 2022
Similar Publications
}
© 2022 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap